Gorham–Stout disease started with recurrent bilateral exudative pleuritis: case description and literature review
- Authors: Lesnyak O.M.1, Pischik V.G.1, Tkach O.N.1, Kunitsina E.S.1
-
Affiliations:
- North-Western State Medical University named after I.I. Mechnikov
- Issue: Vol 28, No 1 (2024)
- Pages: 63-70
- Section: Case report
- URL: https://journals.eco-vector.com/RFD/article/view/625565
- DOI: https://doi.org/10.17816/RFD625565
- ID: 625565
Cite item
Abstract
Gorham–Stout disease is an extremely rare skeletal disorder of unknown etiology manifested by multiple foci of osteolysis (“vanishing bone disease”) and lymphangiomatosis. Osteolysis can occur in any part of the skeleton (skull, facial skeleton, ribs, clavicula, spine, pelvic bones, bones of the upper and lower extremities). Approximately half of the patients develop pleural effusion, accompanied by respiratory abnormalities. We describe a case of Gorham-Stout disease with recurrent bilateral exudative pleuritis as a first and most prominent sign, while the bone lesions at the vertebral bodies, ribs and sternum proceeded without active complaints and were an accidental finding during chest computer tomography. Timely diagnosis of the disease depends on the awareness of doctors of various specialties and careful reading of imaging results.
Keywords
Full Text
About the authors
Olga M. Lesnyak
North-Western State Medical University named after I.I. Mechnikov
Author for correspondence.
Email: olga.m.lesnyak@yandex.ru
ORCID iD: 0000-0002-0143-0614
SPIN-code: 6432-4188
MD, Dr. Sci (Med.), Professor
Russian Federation, Saint PetersburgVadim G. Pischik
North-Western State Medical University named after I.I. Mechnikov
Email: vadim.pischik@mail.ru
ORCID iD: 0000-0002-9602-0908
SPIN-code: 3644-6521
MD, Dr. Sci (Med.), Professor
Russian Federation, Saint PetersburgOlga N. Tkach
North-Western State Medical University named after I.I. Mechnikov
Email: olga.cd@mail.ru
ORCID iD: 0009-0004-3656-5916
Russian Federation, Saint Petersburg
Elena S. Kunitsina
North-Western State Medical University named after I.I. Mechnikov
Email: kunlena1971@mail.ru
ORCID iD: 0009-0006-6881-5136
Russian Federation, Saint Petersburg
References
- Gorham LW, Wright AW, Shultz HH, et al. Disappearing bones: a rare form of massive osteolysis; report of two cases, one with autopsy findings. Am J Med. 1954;17:674–682. doi: 10.1016/0002-9343(54)90027-3
- Gorham LW, Stout AP. Massive osteolysis (acute spontaneous absorption of bone, phantom bone, disappearing bone); its relation to hemangiomatosis. J Bone Joint Surg Am. 1955;37-A(5):985–1004.
- Angelini A, Mosele N, Pagliarini E, Ruggieri P. Current concepts from diagnosis to management in Gorham–Stout disease: a systematic narrative review of about 350 cases. EFORT Open Rev. 2022;7(1):35–48. doi: 10.1530/EOR-21-0083
- Otteva EhN, Kocherova TYu, Shepichev EV. Massive osteolysis – Gorham–Stout syndrome. Osteoporosis and Bone Diseases. 2011;14(1):27–32. EDN: OHKRTR doi: 10.14341/osteo2011127-32
- Nisichenko OA, Bondarenko VP, Minulin IR, et al. Rehabilitation features of patients with Gorham–Stout syndrome. Pediatric Bulletin of the South Ural. 2023;(1):103–111. EDN: AHDSEF doi: 10.34710/Chel.2023.32.48.011
- Domracheva AM, Fomina-Chertousova NA, Sozaeva DI. Development of idiopathic intracranial hypertension on the background of zoledronic acid therapy in Gorham–Stoat syndrome. Medical Herald of the South of Russia. 2023;14(3):46–50. EDN: ZEIARL doi: 10.21886/2219-8075-2023-14-3-46-50
- Kryukov AI, Karpova EP, Toropchina LV, et al. Unilateral subjective tinnitus “vanishing bone” disease (Goram–Stout syndrome). Vestn Otorinolaringol. 2022;87(5):92–98. EDN: TWXBWW doi: 10.17116/otorino20228705192
- Hardegger F, Simpson LA, Segmueller G. The syndrome of idiopathic osteolysis. Classification, review, and case report. J Bone Joint Surg Br. 1985;67(1):88–93. doi: 10.1302/0301-620X.67B1.3968152
- ISSVA Classification of Vascular Anomalies. 2018 [Internet]. International Society for the Study of Vascular Anomalies. Available from: issva.org/classification. Accessed: 03 Jan 2023.
- Ozeki M, Fukao T. Generalized lymphatic anomaly and gorham-stout disease: overview and recent insights. Adv Wound Care (New Rochelle). 2019;8(6):230–245. doi: 10.1089/wound.2018.0850
- Nagy JA, Vasile E, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med. 2002;196(11):1497–1506. doi: 10.1084/jem.20021244
- Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol. 2009;21(2):154–165. doi: 10.1016/j.ceb.2008.12.012
- Hirayama T, Sabokbar A, Itonaga I, et al. Cellular and humoral mechanisms of osteoclast formation and bone resorption in Gorham-Stout disease. J Pathol. 2001;195(5):624–630. doi: 10.1002/path.989
- Liu S, Zhou X, Song A, et al. Successful treatment of Gorham-Stout syndrome in the spine by vertebroplasty with cement augmentation: A case report and literature review. Medicine (Baltimore). 2018;97(29):e11555. doi: 10.1097/MD.0000000000011555
- Heffez L, Doku HC, Carter BL, Feeney JE. Perspectives on massive osteolysis. Report of a case and review of the literature. Oral Surg Oral Med Oral Pathol. 1983;55(4):331–343. doi: 10.1016/0030-4220(83)90185-8
- Di H, Zhang B, Xu N, et al. Refractory serositis in Gorham-Stout syndrome. Orphanet J Rare Dis. 2022;17(1):152. doi: 10.1186/s13023-022-02307-8
- Geeurickx M, Labarque V. A narrative review of the role of sirolimus in the treatment of congenital vascular malformations. J Vasc Surg Venous Lymphat Disord. 2021;9(5):1321–1333. doi: 10.1016/j.jvsv.2021.03.001
- Nadal M, Giraudeau B, Tavernier E, et al. Efficacy and safety of mammalian target of rapamycin inhibitors in vascular anomalies: a systematic review. Acta Derm Venereol. 2016;96(4):448–452. doi: 10.2340/00015555-2300
- Ozeki M, Nozawa A, Yasue S, et al. The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies. Orphanet J Rare Dis. 2019;14(1):141. doi: 10.1186/s13023-019-1118-1
- Shameem R, Lacouture M, Wu S. Incidence and risk of rash to mTOR inhibitors in cancer patients – a meta-analysis of randomized controlled trials. Acta Oncol. 2015;54(1):124–132. doi: 10.3109/0284186X.2014.923583
- Gomez-Fernandez C, Garden BC, Wu S, et al. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis. Eur J Cancer. 2012;48(3):340–346. doi: 10.1016/j.ejca.2011.11.028
- Kuriyama DK, McElligott SC, Glaser DW, Thompson KS. Treatment of Gorham–Stout disease with zoledronic acid and interferon-α: a case report and literature review. J Pediatr Hematol Oncol. 2010;32(8):579–584. doi: 10.1097/MPH.0b013e3181edb464